American Healthcare REIT, Inc.
AHR
$53.84
-1.43%
American Healthcare REIT, Inc. is a healthcare-focused real estate investment trust that owns a diversified portfolio of clinical healthcare properties, including medical office buildings, skilled nursing facilities, senior housing, and hospitals. The company distinguishes itself as a specialized REIT with a broad portfolio spanning integrated senior health campuses, outpatient medical, triple-net leased properties, and SHOP segments, generating the majority of its revenue from integrated senior health campuses. The current investor narrative centers on the company's strong operational momentum, highlighted by 16.4% NOI growth and a 93% share price surge over the past year, driven by institutional buying and improving fundamentals in healthcare real estate. Recent attention also focuses on the company's transition to profitability and its ability to sustain growth amid a favorable demographic tailwind.…
AHR
American Healthcare REIT, Inc.
$53.84
Related headlines
Investment Opinion: Should I buy AHR Today?
Rating: Hold. The thesis is that AHR's operational turnaround and strong revenue growth are priced in at current levels, leaving limited upside without further earnings acceleration. The analyst consensus is bullish (4 Buy, 1 Neutral), but the lack of price targets makes it difficult to quantify upside.
Supporting Evidence: Revenue growth is accelerating (11.3% YoY in Q4 2025), and the company turned profitable with net income of $10.8M. The forward P/E of 64x implies high earnings expectations, while the price-to-sales ratio of 3.46x is elevated. The TTM free cash flow of $225.2M provides some cushion, but the negative quarterly FCF is concerning. Compared to industry averages, the valuation is stretched, but the growth trajectory justifies a premium.
Risks & Conditions: The biggest risks are valuation compression if earnings miss expectations, margin deterioration, and dividend sustainability. This Hold would upgrade to Buy if the forward P/E compresses below 40x or if revenue growth accelerates above 15%. It would downgrade to Sell if net income turns negative again or if the stock breaks below its 50-day moving average. Overall, AHR appears overvalued relative to its history and peers, but the growth story supports a hold for now.
Sign up to view all
AHR 12-Month Price Forecast
AHR's operational momentum is impressive, with accelerating revenue growth and a return to profitability. However, the valuation is extremely stretched, with a trailing P/E of 112x that leaves little room for error. The base case of moderate growth and stable margins is most likely, but the stock's recent surge suggests much of the good news is already priced in. A neutral stance is warranted given the risk/reward balance. An upgrade to bullish would require evidence of sustained margin expansion and a clearer path to earnings growth that justifies the premium. A downgrade to bearish would follow any signs of operational deterioration or a broader market downturn.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on American Healthcare REIT, Inc.'s 12-month outlook, with a consensus price target around $69.99 and implied upside of +30.0% versus the current price.
Average Target
$69.99
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$43 - $70
Analyst target range
Insufficient analyst coverage available. Only one analyst provides estimates, with an average revenue estimate of $4.04 billion for the next fiscal year (range $3.94B to $4.28B). No EPS estimates or price targets are available. The limited coverage implies that AHR is a smaller-cap or recently listed stock (listed in February 2024) with limited institutional interest, which can lead to higher volatility and less efficient price discovery. However, the institutional ratings data shows a bullish consensus: Truist Securities (Buy), Scotiabank (Sector Outperform), Morgan Stanley (Overweight), UBS (Buy), and Citizens (Market Outperform), with only Citigroup rating it Neutral. This suggests that the few analysts covering the stock are overwhelmingly positive, but the lack of a formal consensus target makes it difficult to gauge upside. Investors should monitor for additional analyst initiation or price target updates as the company continues to grow.
Bulls vs Bears: AHR Investment Factors
American Healthcare REIT presents a compelling turnaround story with accelerating revenue growth, a return to profitability, and strong institutional support. However, the stock's valuation is stretched, with a trailing P/E of 112x and forward P/E of 64x, far above industry norms. The key tension lies in whether the company can sustain its earnings growth to justify the premium valuation. If net income continues to rise, the forward P/E could compress rapidly, rewarding investors. Conversely, any slowdown in growth or margin deterioration could lead to a sharp de-rating. Currently, the bull case has stronger evidence given the operational momentum, but the high valuation demands caution.
Bullish
- Strong Revenue Growth Acceleration: Revenue grew 11.3% YoY in Q4 2025 to $604.1M, accelerating from 7.5% in Q2 2025 and 8.2% in Q1 2025. This consistent acceleration indicates strong demand for senior housing and healthcare services.
- Profitability Turnaround Achieved: The company turned profitable in Q4 2025 with net income of $10.8M, compared to a net loss of $31.8M in Q4 2024. Net margin improved from -5.9% to 1.8%, signaling a successful operational turnaround.
- Institutional Buying and Analyst Support: The stock surged 93% over the past year, driven by institutional buying and a bullish consensus from analysts (4 Buy, 1 Neutral). This reflects confidence in the company's growth trajectory.
- Favorable Demographic Tailwinds: As a healthcare-focused REIT, AHR benefits from aging demographics and increasing demand for senior housing and medical facilities. This secular trend supports long-term occupancy and rent growth.
Bearish
- Extremely High Valuation Multiples: Trailing P/E of 112x and forward P/E of 64x are far above the typical healthcare REIT range of 20-30x. The price-to-sales ratio of 3.46x is also elevated, implying high growth expectations that may not materialize.
- Low Gross Margin and Negative FCF: Gross margin dropped to 0.14% in Q4 2025 from 20.7% a year ago, likely due to a shift in revenue mix. Free cash flow was -$14.1M in Q4, though TTM FCF was positive at $225.2M.
- Limited Analyst Coverage and Price Discovery: Only one analyst provides estimates, with no EPS or price targets. This lack of coverage can lead to higher volatility and inefficient pricing, making it harder to gauge fair value.
- High Payout Ratio Risks Dividend: The dividend payout ratio is 234% based on net income, indicating that dividends are not fully covered by earnings. While this may be temporary, it poses a risk if profitability does not continue to improve.
AHR Technical Analysis
American Healthcare REIT is in a sustained uptrend, with a 1-year price change of +51.4%, significantly outperforming the S&P 500's 19.1% gain. The stock closed at $55.04 on July 2, 2026, just 0.1% below its 52-week high of $55.09 and 54.9% above its 52-week low of $35.54, indicating strong momentum and bullish sentiment. Trading near the top of its 52-week range suggests the stock is in a momentum-driven phase, though it may be vulnerable to profit-taking given the extended rally. Short-term momentum is accelerating, with a 1-month price change of +18.7% and a 3-month change of +14.5%, both outpacing the longer-term 6-month change of +16.5%. The 1-month relative strength versus SPY is +19.9%, confirming strong recent outperformance. However, the 3-month relative strength is only +0.9%, suggesting the stock has recently re-accelerated after a period of consolidation. The stock's beta of 0.78 indicates it is less volatile than the market, which is unusual given the recent sharp gains, but may reflect the defensive nature of healthcare REITs. The 52-week high of $55.09 serves as immediate resistance; a breakout above this level would signal further upside potential. Support lies at the 52-week low of $35.54, though the stock is far above that level. The current ratio of 0.37 and debt-to-equity of 0.51 suggest moderate financial leverage, but the low beta implies that the stock's volatility is lower than the market's, which may appeal to risk-averse investors.
Beta
0.78
0.78x market volatility
Max Drawdown
-14.1%
Largest decline past year
52-Week Range
$36-$56
Price range past year
Annual Return
+49.4%
Cumulative gain past year
| Period | AHR Return | S&P 500 |
|---|---|---|
| 1m | +15.3% | +2.0% |
| 3m | +9.4% | +10.6% |
| 6m | +13.9% | +8.3% |
| 1y | +49.4% | +20.4% |
| ytd | +14.0% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AHR Fundamental Analysis
Revenue has been growing steadily, with Q4 2025 revenue of $604.1 million representing 11.3% year-over-year growth, up from $542.7 million in Q4 2024. The multi-quarter trend shows accelerating growth: Q3 2025 revenue was $572.9 million (up 9.4% YoY), Q2 2025 was $542.5 million (up 7.5% YoY), and Q1 2025 was $540.6 million (up 8.2% YoY). The primary revenue driver is resident fees and services, which accounted for $564.0 million in the latest quarter, indicating strong demand for senior housing and healthcare services. The company turned profitable in Q4 2025, reporting net income of $10.8 million compared to a net loss of $31.8 million in Q4 2024. Gross margin improved dramatically to 0.14% in Q4 2025 from 20.7% in Q4 2024, though this is due to a change in revenue mix (likely higher pass-through costs). Operating margin was 6.6% in Q4 2025, down from 7.4% in Q3 2025 but up from 5.5% in Q1 2025. Net margin turned positive at 1.8% in Q4 2025, compared to -5.9% a year ago, signaling improving profitability. The company has a debt-to-equity ratio of 0.51, which is moderate for a REIT, and generated free cash flow of -$14.1 million in Q4 2025, though trailing twelve-month free cash flow was $225.2 million. Return on equity (ROE) was 2.1% as of the latest data, and the current ratio of 0.37 indicates low liquidity, which is typical for REITs that rely on property cash flows. The company's ability to generate positive net income and operating cash flow ($55.2 million in Q4 2025) supports its dividend, which has a payout ratio of 234% based on net income, but this is likely temporary as earnings improve.
Quarterly Revenue
$604080000.0B
2025-12
Revenue YoY Growth
+11.30%
YoY Comparison
Gross Margin
0.14%
Latest Quarter
Free Cash Flow
$225183000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AHR Overvalued?
Since net income is positive (TTM net income of $10.8 million), the primary valuation metric is the P/E ratio. The trailing P/E is 112.0x, while the forward P/E is 64.0x, implying that the market expects significant earnings growth. The gap between trailing and forward P/E suggests that analysts anticipate a sharp increase in earnings, which is consistent with the company's recent turnaround to profitability. Compared to the industry average (not provided, but healthcare REITs typically trade at P/E ratios around 20-30x), AHR's trailing P/E of 112x appears extremely expensive. However, the forward P/E of 64x still represents a substantial premium, likely justified by the company's high growth rate and improving margins. The price-to-sales ratio of 3.46x is also elevated relative to historical levels, reflecting the market's optimism. Historically, AHR's P/E ratio has ranged from negative (when unprofitable) to as high as 243x in Q2 2024. The current trailing P/E of 112x is near the lower end of its recent positive range, suggesting that while the stock is not cheap, it is not at extreme historical highs either. The price-to-book ratio of 2.35x is above the historical average of around 1.0x, indicating that the market is pricing in future growth and asset appreciation. Overall, the valuation reflects high expectations for continued earnings improvement and NOI growth.
PE
112.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -211x~243x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The company's debt-to-equity ratio of 0.51 is moderate for a REIT, but the current ratio of 0.37 indicates low liquidity, which is typical but could strain operations if cash flows weaken. The negative free cash flow of -$14.1M in Q4 2025, despite positive TTM FCF, suggests that cash generation is inconsistent. The high payout ratio of 234% means dividends are not fully covered by net income, posing a risk if earnings falter. Additionally, the gross margin collapsed to 0.14% in Q4 2025 from 20.7% a year ago, signaling a shift in revenue mix that could pressure profitability if not managed.
Market & Competitive Risks: The stock's trailing P/E of 112x is extremely high relative to healthcare REIT peers (typically 20-30x), making it vulnerable to valuation compression if growth disappoints. The beta of 0.78 suggests lower market correlation, but the stock's recent 51.4% surge may attract profit-taking. Limited analyst coverage (only one analyst) reduces price discovery and could lead to higher volatility. Regulatory changes in healthcare reimbursement or senior housing could also impact occupancy and rent growth.
Worst-Case Scenario: If revenue growth decelerates, margins fail to improve, or the company returns to net losses, the stock could re-rate sharply. The 52-week low of $35.54 represents a potential 35.4% downside from the current price of $55.04. In a severe downturn, the stock could test that level, especially if the broader market corrects or if the company faces operational setbacks. Investors could lose up to 35% in this adverse scenario.
FAQ
The key risks are: 1) Valuation risk: Trailing P/E of 112x leaves little room for error; any earnings miss could trigger a sharp sell-off. 2) Margin risk: Gross margin collapsed to 0.14% in Q4 2025, and if it does not recover, profitability could suffer. 3) Dividend risk: The payout ratio of 234% suggests dividends are not fully covered by earnings, potentially leading to a cut. 4) Coverage risk: Only one analyst provides estimates, leading to less efficient price discovery and higher volatility. The most severe risk is a 35% decline to the 52-week low if growth stalls.
The 12-month outlook is mixed. The bull case (30% probability) sees the stock reaching $60-$70, driven by sustained growth and margin expansion. The base case (50% probability) expects the stock to trade between $50 and $60 as growth moderates. The bear case (20% probability) could see the stock fall to $35-$45 if growth disappoints. The most likely scenario is the base case, where the stock consolidates recent gains. The key assumption is that revenue growth remains above 8% and net margins stay positive.
AHR appears overvalued relative to its peers and its own history. The trailing P/E of 112x is far above the typical healthcare REIT range of 20-30x, and the forward P/E of 64x still implies a significant premium. The price-to-sales ratio of 3.46x is also elevated. However, the company's high growth rate and recent turnaround to profitability justify some premium. The market is pricing in aggressive earnings growth, and if that materializes, the valuation could compress quickly. Currently, the stock is overvalued based on traditional metrics, but it may be fairly valued if growth expectations are met.
AHR is a high-risk, high-reward stock. The company has strong operational momentum with 11.3% revenue growth and a return to profitability, but the trailing P/E of 112x is extremely expensive. The analyst consensus is bullish, but limited coverage means less price discovery. For growth-oriented investors with a long-term horizon, AHR could be a good buy if earnings continue to improve. However, value-conscious investors may find the valuation unattractive. The biggest downside risk is a 35% drop to the 52-week low of $35.54 if growth disappoints.
AHR is better suited for long-term investment given its growth stage and favorable demographic tailwinds. The beta of 0.78 indicates lower volatility, but the stock's recent 51.4% surge suggests it may be overextended in the short term. Short-term traders could capitalize on momentum, but the high valuation and limited coverage increase risk. A minimum holding period of 2-3 years is recommended to allow the company's earnings growth to catch up with the valuation. The dividend yield of 2.09% provides some income, but the payout ratio is high.